
Victoria Werth, MD, highlights CLE treatment gaps and how BDCA2-targeting litifilimab may quickly curb interferon-driven skin disease with less toxicity.
Victoria Werth, MD, is a professor of Dermatology and Medicine at the University of Pennsylvania and Chief of Dermatology at the Philadelphia VA Medical Center.

Victoria Werth, MD, highlights CLE treatment gaps and how BDCA2-targeting litifilimab may quickly curb interferon-driven skin disease with less toxicity.